Clinical trial
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease…
NCT00891202 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00891202 |
|---|---|
| Title | A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE) |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE) |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gaucher Disease, Type 1 |
| Intervention type | Drug |
| Interventions | Eliglustat tartrate, Placebo |
| Enrollment | 40 |
| Start date | Nov 1, 2009 |
| Primary completion | Jul 1, 2012 |
| Completion | Jan 1, 2016 |
| First posted | May 1, 2009 |
| Last update posted | Mar 3, 2017 |
| Countries | Bulgaria, Canada, Colombia, India, Israel, Lebanon, Mexico, Russia, Serbia, Tunisia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: